<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00729482</url>
  </required_header>
  <id_info>
    <org_study_id>AMC-ONCGI-0801</org_study_id>
    <nct_id>NCT00729482</nct_id>
  </id_info>
  <brief_title>RAD001 (Everolimus) Salvage Monotherapy in Advanced Gastric Cancer (AGC) Who Failed Standard First-line Treatment</brief_title>
  <official_title>A Phase II Study of RAD001 (Everolimus) in Patients With Fluoropyrimidine and Platinum-refractory Advanced Gastric Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Asan Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Asan Medical Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a phase II study to evaluate RAD001 (Everolimus) in terms of 4-month progression-free
      survival rate (primary end-point) and response rate, toxicity, and overall survival
      (secondary end-points) in patients with metastatic and/or advanced inoperable gastric cancer.

      Eligibility criteria include histologically proven gastric/gastroesophageal junction cancer
      who failed previous first-line standard treatment with fluoropyrimidine and platinum-based
      chemotherapy.

      Oral RAD001 (everolimus) 10mg daily will be administered and the dose will be adjusted
      according to the observed clinical toxicities. Treatment will be continued until disease
      progression or patient's intolerability to the study drug.

      Total of 54 patients will be enrolled to decide whether the proportion of patients who are
      free from progression at 4 months (16 weeks), P, is less that or equal to 0.15 or greater
      than or equal to 0.30 to assess the treatment outcome in 48 patients assuming drop-out rate,
      10%.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>July 2008</start_date>
  <completion_date type="Actual">March 2013</completion_date>
  <primary_completion_date type="Actual">September 2011</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Progression-free Survival Rate at 4-month (16 Weeks)</measure>
    <time_frame>4 months (16 weeks)</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Response Rate</measure>
    <time_frame>2years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Toxicity Profiles (According to National Cancer Institute Common Terminology Criteria for Adverse Events Version 3.0)</measure>
    <time_frame>up to 24 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">54</enrollment>
  <condition>Stomach Neoplasm</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Treatment Arm (RAD001)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>RAD001</intervention_name>
    <description>RAD001 (everolimus) 10mg daily administration orally until disease progression and/or intolerability</description>
    <arm_group_label>1</arm_group_label>
    <other_name>everolimus</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients must have histologically or cytologically documented stomach adenocarcinoma
             including adenocarcinoma of the esophagogastric junction

          -  Patients must have non-resectable disease by metastasis or recurrent disease after
             curative surgical resection with uni-dimensionally measurable disease (at least
             longest diameter 1 cm on computed tomography scan, or at least 2 cm on chest x-ray or
             physical examination)

          -  Patients tumor should have failure of 1st line chemotherapy including fluoropyrimidine
             (5-FU, capecitabine, doxifluridine, S1, or UFT) and platinum (cisplatin, carboplatin,
             or oxaliplatin) in palliative setting; progression during or within 6 months after
             chemotherapy

          -  Age 18 to 75 years old

          -  Estimated life expectancy of more than 3 months

          -  ECOG performance status of 2 or lower

          -  Adequate bone marrow function

          -  Adequate kidney function

          -  Adequate liver function

          -  No prior radiation therapy to more than 25 percent of BM

          -  Patients must not have psychological, familial, sociological or geographical
             conditions which do not permit medical follow-up and compliance with this study

          -  Women of childbearing potential must have a negative pregnancy test on admission

          -  The patient must be able to understand the study and has given written informed
             consent to participate in the study

        Exclusion Criteria:

          -  Other tumor types than adenocarcinoma

          -  Central nervous system metastases or prior radiation for CNS metastasis

          -  Gastric outlet obstruction or intestinal obstruction

          -  Evidence of active gastrointestinal bleeding

          -  Bony metastasis as the sole evaluable disease

          -  Past or concurrent history of neoplasm other than stomach cancer

          -  Pregnant or lactating women, women of childbearing potential not employing adequate
             contraception

          -  Thyroid disease
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Asan Medical Center</name>
      <address>
        <city>Seoul</city>
        <state>Songpa</state>
        <zip>138-736</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>December 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 4, 2008</study_first_submitted>
  <study_first_submitted_qc>August 4, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 7, 2008</study_first_posted>
  <results_first_submitted>December 31, 2013</results_first_submitted>
  <results_first_submitted_qc>December 31, 2013</results_first_submitted_qc>
  <results_first_posted type="Estimate">February 13, 2014</results_first_posted>
  <last_update_submitted>December 31, 2013</last_update_submitted>
  <last_update_submitted_qc>December 31, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 13, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Asan Medical Center</investigator_affiliation>
    <investigator_full_name>Yoon-Koo Kang</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>RAD001 (everolimus)</keyword>
  <keyword>second-line treatment</keyword>
  <keyword>advanced gastric cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Stomach Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Everolimus</mesh_term>
    <mesh_term>Sirolimus</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>RAD001</title>
          <description>Treatment Arm (RAD001)</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="54"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="54"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Baseline analysis was based on all enrolled patients.</population>
      <group_list>
        <group group_id="B1">
          <title>RAD001</title>
          <description>Treatment Arm (RAD001)</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="54"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age, Customized</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <title>Age_median</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="57.5" lower_limit="27" upper_limit="72"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Korea, Republic of</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="54"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Progression-free Survival Rate at 4-month (16 Weeks)</title>
        <time_frame>4 months (16 weeks)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>RAD001</title>
            <description>Treatment Arm (RAD001)</description>
          </group>
        </group_list>
        <measure>
          <title>Progression-free Survival Rate at 4-month (16 Weeks)</title>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="54"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Response Rate</title>
        <time_frame>2years</time_frame>
        <population>51 patients were available for response assessments.</population>
        <group_list>
          <group group_id="O1">
            <title>RAD001</title>
            <description>Treatment Arm (RAD001)</description>
          </group>
        </group_list>
        <measure>
          <title>Response Rate</title>
          <population>51 patients were available for response assessments.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="51"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Overall Survival</title>
        <time_frame>1 year</time_frame>
        <group_list>
          <group group_id="O1">
            <title>RAD001</title>
            <description>Treatment Arm (RAD001)</description>
          </group>
        </group_list>
        <measure>
          <title>Overall Survival</title>
          <units>Months</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="54"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.3" lower_limit="4.5" upper_limit="12.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Toxicity Profiles (According to National Cancer Institute Common Terminology Criteria for Adverse Events Version 3.0)</title>
        <time_frame>up to 24 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>RAD001</title>
            <description>Treatment Arm (RAD001)</description>
          </group>
        </group_list>
        <measure>
          <title>Toxicity Profiles (According to National Cancer Institute Common Terminology Criteria for Adverse Events Version 3.0)</title>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="54"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="54"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>At least 6 months after last dose of chemotherapy.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>RAD001</title>
          <description>Treatment Arm (RAD001)</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>NCI_CTC_v3.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="54"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Sudden death</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="54"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Ileus</sub_title>
                <description>Grade 2 paralytic intestinal obstruction</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="54"/>
              </event>
              <event>
                <sub_title>Gastrointestinal bleeding</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="54"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="54"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>NCI_CTC_v3.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="54" subjects_at_risk="54"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Neutropenia</sub_title>
                <counts group_id="E1" subjects_affected="23" subjects_at_risk="54"/>
              </event>
              <event>
                <sub_title>Anemia</sub_title>
                <counts group_id="E1" subjects_affected="51" subjects_at_risk="54"/>
              </event>
              <event>
                <sub_title>Thrombocytopenia</sub_title>
                <counts group_id="E1" subjects_affected="47" subjects_at_risk="54"/>
              </event>
              <event>
                <sub_title>Hemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="18" subjects_at_risk="54"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" subjects_affected="19" subjects_at_risk="54"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="54"/>
              </event>
              <event>
                <sub_title>Anorexia</sub_title>
                <counts group_id="E1" subjects_affected="43" subjects_at_risk="54"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="21" subjects_at_risk="54"/>
              </event>
              <event>
                <sub_title>Stomatitis</sub_title>
                <counts group_id="E1" subjects_affected="41" subjects_at_risk="54"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Asthenia</sub_title>
                <counts group_id="E1" subjects_affected="52" subjects_at_risk="54"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Hyperbilirubinemia</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="54"/>
              </event>
              <event>
                <sub_title>Elevated alkaline phosphatase</sub_title>
                <counts group_id="E1" subjects_affected="18" subjects_at_risk="54"/>
              </event>
              <event>
                <sub_title>Elevated aspartate aminotransferase</sub_title>
                <counts group_id="E1" subjects_affected="32" subjects_at_risk="54"/>
              </event>
              <event>
                <sub_title>Elevated alanine aminotransferase</sub_title>
                <counts group_id="E1" subjects_affected="20" subjects_at_risk="54"/>
              </event>
              <event>
                <sub_title>Elevated gamma glutamyl transpeptidase</sub_title>
                <counts group_id="E1" subjects_affected="17" subjects_at_risk="54"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Hypercholesterolemia</sub_title>
                <counts group_id="E1" subjects_affected="24" subjects_at_risk="54"/>
              </event>
              <event>
                <sub_title>Triacylglyceridemia</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="54"/>
              </event>
              <event>
                <sub_title>Hyperglycemia</sub_title>
                <counts group_id="E1" subjects_affected="47" subjects_at_risk="54"/>
              </event>
              <event>
                <sub_title>Hypophosphatemia</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="54"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" subjects_affected="20" subjects_at_risk="54"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Hyponatremia</sub_title>
                <counts group_id="E1" subjects_affected="24" subjects_at_risk="54"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Pneumonitis</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="54"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Skin rash</sub_title>
                <counts group_id="E1" subjects_affected="35" subjects_at_risk="54"/>
              </event>
              <event>
                <sub_title>Hand-foot syndrome</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="54"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Yoon-Koo Kang</name_or_title>
      <organization>Asan Medical Center</organization>
      <phone>+82-2-3010-3210</phone>
      <email>ykkang@amc.seoul.kr</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

